Manager TitleAgeSince
Chief Operating Officer - 14/11/2022
Director TitleAgeSince
Director/Board Member 61 16/08/2005
Chairman 67 19/09/2014
Director/Board Member 56 05/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+14.62% - - 1.28M
+4.98%+11.06%+54.45%+109.45% 70.88B
-0.39%+1.66%+38.84%+78.01% 62.49B
+5.26%+12.77%+40.29%+26.34% 26.34B
+0.83%-3.43%-16.57%+359.38% 26.21B
+2.02%-0.87%-0.73%-7.92% 24.13B
0.00%+8.03%+25.03%-13.74% 20.72B
-2.54%-10.16%+149.64%+313.93% 15.69B
-1.95%+1.80%+44.57%+165.15% 14.46B
-5.32%-8.25%-11.52%+823.50% 14.24B
Average +0.54%+1.96%+36.00%+206.01% 30.57B
Weighted average by Cap. +1.63%+2.90%+37.22%+150.13%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!